Expression of FGF-2 and IGF-1 in diabetic rats with fracture

Objective:To observe the change of fibroblast growth factor-2(FGF-2),insulin-like growth factor-1(IGF—1)in serum and bone callus after fracture in diabetic rats,and to explore molecular biological mechanism of healing of diabetic fracture.Methods:Thirty male SD rats were designed into normal(n=13)and control(n=!5)groups randomly.Venous blood was extracted on the 1st,2nd,4th,6th,8th week after surgery.It was certificated and the serum was obtained.Left lower extremity was observed by X-ray.Bone callus at broken ends was observed under light microscope.Expressions of FGF-2 and 1GF-1 in tissue were detected by immunohistochemistry method,and ELISA was used to detect expression of FGF-2 and IGF-I in serum.Results:The results showed a significant increase in the density and area of newly formed bone in the distraction gaps of normal rats compared to control rats.Increased cell proliferation was also found in the distraction gaps of normal rats versus control rats.There was significant difference in serum levels of FGF-2 and IGF-1 between two groups.Conclusions:The decrease of FGF-2 and IGF-1 both in the serum and in the fracture region is one of the reasons for bad bone healing or delayed union in rats'fracture with diabetes.There are some synergistic effects possibly between FGF-2 and ICF-I.

THE MECHANICAL RELATIONSHIP TO THE FORMATION AND DISTRIBUTION OF THEBURIED HILLS AND THE DEEP-SEATED FRACTURAL ZONE IN THE DIWA-TYPE FAULTED BASIN IN CENTRAL HEBEI PROVINCE,CHINA

The author proves the existence and movement of a deep-seated fraetural Zone located in the eenter zone of the diwa-type faulted basin in central Hebei Province. This deep-seated fraeturai zone tending in NNE direction is a structural effect of the mtodle East Asin Grustobody in the Mexozoic-Cenozoic. This paper will diseuss the formation, evolution and the meehanism of the deep-seated fraetural zone, faulted basin and the buried hills as well as their relationships. The uthor expounds that the deep geological process is the major factor of the structural effect.

Comparison of parathyroid hormone （1-34） and elcatonin in postmenopausal women with osteoporosis： an 18-month randomized, multicenter controlled trial in China

Background Recombinant human parathyroid hormone （1-34） （rhPTH （1-34）） is the first agent in a unique class of anabolic therapies acting on the skeleton. The efficacy and safety of long-term administration of rhPTH （1-34） in Chinese postmenopausal women had not been evaluated. This study compared the clinical efficacy and safety of rhPTH （1-34） with elcatonin for treating postmenopausal women with osteoporosis in 11 urban areas of China. Methods A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study. They were randomized to receive either rhPTH （1-34） 20 μg （200 U） daily for 18 months, or elcatonin 20 U weekly for 12 months. Lumbar spine （L1-4） and femoral neck bone mineral density （BMD）, fracture rate, back pain as well as biochemical markers of bone turnover were measured. Adverse events were recorded. Results rhPTH （1-34） increased lumbar BMD significantly more than did elcatonin after 6, 12, and 18 months of treatment （4.3% vs. 1.9%, 6.8% vs. 2.7%, 9.5% vs. 2.9%, P 〈0.01）. There was only a small but significant increase of femoral neck BMD after 18 months （2.6%, P 〈0.01） in rhPTH groups. There were larger increases in bone turnover markers in the rhPTH （1-34） group than those in the elcatonin group after 6, 12, and 18 months （serum bone-specific alkaline phosphatase （BSAP） 93.7% vs. -3.6%; 117.8% vs. -4.1%; 49.2% vs. -5.8%, P 〈0.01; urinary C-telopeptide/creatinine （CTX/Cr） 250.0% vs. -29.5%; 330.0% vs. -41.4%, 273.0% vs. -10.6%, P 〈0.01）. rhPTH （1-34） showed similar effect of pain relief as elcatonin. The incidence of clinical fractures was 5.36% （6/112） in elcatonin group and 3.2% （11/341）in rhPTH （1-34）group （P=0.303）. Both treatments were well tolerated. Hypercaluria （9.4%） and hypercalcemia （7.0%） in rhPTH （1-34） group were transient and caused no clinical symptoms. Pruritus （8.2% vs. 2.7%, P=0.044） and redness of injection site （4.4% vs. 0,P=0.024） were more frequent in rhPTH （1-34）. Nausea/vomiting （16.1% vs. 6.2%, P=0.001） and hot flushes （7.1% vs. 0.6%, P 〈0.001） were more common in elcatonin group. Conclusions rhPTH （1-34） was associated with greater increases in lumbar spine BMD and bone formation markers. It could increase femoral BMD after 18 months of treatment, rhPTH could improve back pain effectively. The results of the present study indicate that rhPTH （1-34） is an effective, safe agent in treating Chinese postmenopausal women with osteoporosis. （ChiCTR- TRC-10000924）